Early and High-Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation.

Clin Pharmacol Ther · 2026 · PMC13438008 · PMID 42552645

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In contrast, later exposure and intermediate‐dose glucocorticoid exposure were not associated with a significant difference in mortality risk, while low‐dose glucocorticoid exposure showed a nonsignificant trend toward lower mortality.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.